Evidence map›Paper›PMID 36834763›Full record

ArticleInternational journal of molecular sciences2023

Inhibitory Effects of a Novel μ-Opioid Receptor Nonpeptide Antagonist, UD-030, on Morphine-Induced Conditioned Place Preference.

Soichiro Ide, Noriaki Iwase, Kenichi Arai, Masahiro Kojima, Shigeru Ushiyama, Kaori Taniko, Kazutaka Ikeda

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Soichiro IdeAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Noriaki IwaseUBE Corporation, Yamaguchi 755-8633, Japan.
Kenichi AraiUBE Corporation, Yamaguchi 755-8633, Japan.
Masahiro KojimaUBE Corporation, Yamaguchi 755-8633, Japan.
Shigeru UshiyamaUBE Corporation, Yamaguchi 755-8633, Japan.
Kaori TanikoSanwa Kagaku Kenkyusho Co., Ltd., Aichi 461-8631, Japan.
Kazutaka IkedaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.ORCID 0000-0001-8342-0278
Ube (Japan) · JPTokyo Metropolitan Institute of Medical Science · JPRiso Kagaku (Japan) · JP

Funding

Japan Society for the Promotion of Science 21H03028Japan Society for the Promotion of Science 21K06814Japan Society for the Promotion of Science 22H04922 (AdAMS)UBE Corporation a joint research fund
6 · The paper itself

Abstract

Although opioids are widely used to treat moderate to severe pain, opioid addiction and the opioid overdose epidemic are becoming more serious. Although opioid receptor antagonists/partial agonists, such as naltrexone and buprenorphine, have relatively low selectivity for the μ-opioid receptor (MOP), they have been used for the management of opioid use disorder. The utility of highly selective MOP antagonists remains to be evaluated. Here, we biologically and pharmacologically evaluated a novel nonpeptide ligand, UD-030, as a selective MOP antagonist. UD-030 had more than 100-fold higher binding affinity for the human MOP (K

Indexed as

Narcotic AntagonistsOpioid-Related DisordersAnalgesics, OpioidAnimalsHumansMiceMice, Inbred C57BLMorphineNaltrexoneReceptors, Opioid, deltaReceptors, Opioid, muAnalgesics, OpioidMorphineNaltrexoneNarcotic AntagonistsReceptors, Opioid, deltaReceptors, Opioid, muaddictionCPPmorphinenaltrexoneopioid receptor antagonistreward

Identifiers

PMID36834763
PMCPMC9961271
OpenAlexW4319600105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.